Skip to main content
SpringerLink
Log in

Everolimus

In Advanced Renal Cell Carcinoma

  • ADis Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

  • ▲ Everolimus is an orally administered, targeted therapy indicated for the treatment of advanced renal cell carcinoma. It inhibits the mammalian target of rapamycin, an integral component of multiple pathways involved in cell growth and proliferation.

  • ▲ Median progression-free survival was significantly longer with everolimus 10 mg once daily than with placebo in both second interim (4.0 vs 1.9 months) and updated (4.9 vs 1.9 months) analyses of a randomized, double-blind, placebo-controlled, multicentre, phase III trial in patients with metastatic renal cell carcinoma that had progressed while receiving sunitinib and/or sorafenib treatment.

  • ▲ At the second interim analysis, median overall survival was 8.8 months for placebo recipients; at this analysis, overall survival had not yet been reached for everolimus recipients.

  • ▲ With regard to objective response at the second interim analysis, 64% of everolimus and 32% of placebo recipients had either a partial response (1% and 0%) or stable disease (63% and 32%).

  • ▲ The tolerability profile of everolimus was largely manageable in the phase III trial, with most treatment-related adverse events being of grade 1 or 2 severity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Bellmunt J, Guix M. The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations. BJU Int 2009 Mar; 103(5): 572–7

    Article  PubMed  CAS  Google Scholar 

  2. Kroog GS, Motzer RJ. Systemic therapy for metastatic renal cell carcinoma. Urol Clin North Am 2008 Nov; 35(4): 687–701

    Article  PubMed  Google Scholar 

  3. Bellmunt J. Future developments in renal cell carcinoma. Ann Oncol 2009 May; 20 Suppl. 1: i13–7

    Article  PubMed  Google Scholar 

  4. Escudier B. Signaling inhibitors in metastatic renal cell carcinoma. Cancer J 2008 Sep/Oct; 14(5): 325–9

    Article  PubMed  CAS  Google Scholar 

  5. Escudier B, Thompson JA. Mechanism of action of everolimus in renal cell carcinoma. Med Oncol 2009; 26 Suppl. 1: S32–9

    Article  CAS  Google Scholar 

  6. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer v.2.2009 [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf [Accessed 2009 Jul 27]

  7. Dunn C, Croom KF. Everolimus: a review of its use in renal and cardiac transplantation. Drugs 2006; 66(4): 547–70

    Article  PubMed  CAS  Google Scholar 

  8. Chapman TM, Perry CM. Everolimus. Drugs 2004; 64(8): 861–72

    Article  PubMed  CAS  Google Scholar 

  9. Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007 Jun 1; 13(11): 3109–14

    Article  PubMed  CAS  Google Scholar 

  10. Boulay A, Zumstein-Mecker S, Stephan C, et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004 Jan 1; 64(1): 252–61

    Article  PubMed  CAS  Google Scholar 

  11. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997 Jul 15; 64(1): 36–42

    Article  PubMed  CAS  Google Scholar 

  12. Fingar DC, Salama S, Tsou C, et al. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 2002 Jun 15; 16(12): 1472–87

    Article  PubMed  CAS  Google Scholar 

  13. Fingar DC, Richardson CJ, Tee AR, et al. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 2004 Jan; 24(1): 200–16

    Article  PubMed  CAS  Google Scholar 

  14. Shinohara ET, Cao C, Niermann K, et al. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 2005 Aug 18; 24(35): 5414–22

    Article  PubMed  CAS  Google Scholar 

  15. Lane HA, Wood JM, McSheehy PM, et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 2009 Mar 1; 15(5): 1612–22

    Article  PubMed  CAS  Google Scholar 

  16. Novartis Pharmaceuticals Corporation. Afinitor (everolimus tablets): US prescribing information [online]. Available from URL: http://www.pharma.us.novartis.com/product/pi/pdf/afinitor.pdf [Accessed 2009 Jun 24]

  17. O’Donnell A, Faivre S, Burris HA, et al. Phase I pharmaco-kinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008 Apr 1; 26(10): 1588–95

    Article  PubMed  Google Scholar 

  18. Tabernero J, Rojo F, Calvo E, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamyci pathway with everolimus: a phase I tumour pharmacodynamic study in patients with advanced solid tumours. J Clin Oncol 2008; 26(10): 1603–10

    Article  PubMed  CAS  Google Scholar 

  19. Tanaka C, O’Reilly T, Kovarik JM, et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 2008 Apr 1; 26(10): 1596–602

    PubMed  CAS  Google Scholar 

  20. US FDA. Center for Drug Evaluation and Research clinical pharmacology and biopharmaceutics review for everolimus [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022334s000_ClinPharmR.pdf [Accessed 2009 Jul 27]

  21. O’Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006 Feb 1; 66(3): 1500–8

    Article  PubMed  Google Scholar 

  22. Rosenberg JE, Weinberg VK, Claros C, et al. Phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma [abstract no. 5109]. J Clin Oncol 2008 May; 26 (15 Suppl., Part I of II): 276S

    Google Scholar 

  23. Kovarik JM, Hartmann S, Figueiredo J, et al. Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants. Pharmacotherapy 2002 Feb; 22(2): 154–9

    Article  PubMed  CAS  Google Scholar 

  24. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008 Aug 9; 372(9637): 449–56

    Article  PubMed  CAS  Google Scholar 

  25. Kay A, Motzer R, Figlin R, et al. Updated data from a phase III randomized trial of Everolimus versus PBO in metastatic renal cell carcinoma [abstract no. 278]. 2009 Genitourinary Cancers Symposium; 2009 Feb 26–28; Orlando (FL) [online]. Available from URL: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=64&abstractID=20488 [Accessed 2009 Jun 06]

  26. Amato RJ, Jac J, Giessinger S, et al. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009 Jun 1; 115(11): 2438–46

    Article  PubMed  CAS  Google Scholar 

  27. Jac J, Amato RJ, Giessinger S, et al. A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic renal cell carcinoma which has progressed on tyrosine kinase inhibition therapy [abstract no. 5113]. J Clin Oncol 2008; 26 (15 Suppl. Pt 1): s277. Plus poster presented at the 44th Annual Meeting of the American Society of Clinical Oncology; 2008 May 30–Jun 3; Chicago (IL)

    Google Scholar 

  28. Whorf RC, Hainsworth JD, Spigel DR, et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma [abstract no. 5010]. J Clin Oncol 2008 May; 26 (15 Suppl., part I of II): 252s

    Google Scholar 

  29. Chan JS, Vuky J, Besaw LA, et al. A phase II study of mammalian target of rapamycin inhibitor RAD001 plus imatinib mesylate in patients with previously treated advanced renal carcinoma [abstract no. 15600]. J Clin Oncol; 25 (18 Suppl., Part I of II) [online]. Available from URL: http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/15600 [Accessed 2009 Jun 04]

  30. Novartis Pharmaceuticals Corporation. Afinitor® approved in EU as first treatment proven to benefit patients with advanced kidney cancer after failure of targeted therapy [online media release]. 2009 Aug 6. Available from URL: http://www.novartis.com/newsroom/media-releases/en/2009/1332932.shtml [Accessed 2009 Sep 18]

Download references

Acknowledgements and Disclosures

The manuscript was reviewed by: D. Cho, Division of Hematology and Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; I. Davis, Ludwig Institute for Cancer Research, Melbourne, Victoria, Australia.

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, a Wolters Kluwer Business, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    Karly P. Garnock-Jones & Gillian M. Keating

Authors
  1. Karly P. Garnock-Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karly P. Garnock-Jones.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Garnock-Jones, K.P., Keating, G.M. Everolimus. Drugs 69, 2115–2124 (2009). https://doi.org/10.2165/11203770-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11203770-000000000-00000

Keywords

Search

Navigation